

GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS

LOK SABHA

UNSTARRED QUESTION No. 1956

TO BE ANSWERED ON THE 14th March, 2017

Capping Price of Stents

1956. SHRI K.C. VENUGOPAL, SHRI M. RAJA MOHAN REDDY, SHRIMATI VEENA DEVI, SHRI C.N. JAYADEVAN, SHRI B. VINOD KUMAR, SHRI B. SRIRAMULU, SHRI MULLAPPALLY RAMACHANDRAN, SHRI PRABHAKAR REDDY KOTHA

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether the Government has capped the price of coronary stents lower than the existing market level and if so, the details thereof along with the regulatory changes which allowed stents to be brought under price control;
- (b) the measures taken by the Government to monitor the implementation of the discounted price of stents and ensure its availability in Government and private hospitals and labs in the country;
- (c) whether the capping of price of stents include imported ones also and if so, the details thereof along with the steps taken for quality control of imported stents; and
- (d) whether the Government also proposes to bring certain drugs/medical devices under price control and if so, the details thereof?

ANSWER

MINISTER OF STATE FOR CHEMICALS & FERTILIZERS, ROAD TRANSPORT & HIGHWAYS AND SHIPPING (SHRI MANSUKH L. MANDAVIYA)

(a): National Pharmaceutical Pricing Authority (NPPA) notified the ceiling price of Coronary Stent vide its notification dated 13th February 2017 at INR 7,260/- for Bare Metal Stent and INR 29,600/- for Drug Eluting Stents (DES)

including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents. The average MRP before this notification was INR 45,100 for Bare Metal Stent (BMS) and INR 121,400 for Drug Eluting Stent (DES). The Drug Price Control Order, 2013 (DPCO, 2013) empowers NPPA to regulate the prices of essential drugs notified in Schedule-I of DPCO, 2013. Government included Coronary Stents in the National List of Essential Medicines, 2015 in July 2016 and subsequently in Schedule-I of DPCO, 2013 in December 2016.

(b): Government through NPPA is closely monitoring the situation and has alerted the State Governments and State Drugs Controllers to monitor the availability of stents. NPPA has also requested aggrieved persons to send verifiable information/complaints on help line number of NPPA, through online complaint mechanism (Pharma Jan Samadhan) or on Whatsapp. Industry has been appraised that all manufactures/importers are under legal obligation to maintain smooth production and supply of coronary stents of all brands which were available in the country before price cap.

(c): The price capping is applicable to imported as well as indigenous stents. Import license is issued subject to the condition that the licensee shall withdraw from sale any part of any batch of the imported stents being found not conforming with the quality standards prescribed under the Drugs and Cosmetics Act, 1940 and the Rules thereunder.

(d): At present, there is no proposal to revise Schedule-I of DPCO, 2013.

XXXX